BAZ1B and breast cancer: Interestingly, combining siRNA-mediated silencing of BAZ1B with silencing or pharmacological inhibition of Dot1L and menin resulted in more pronounced reduction of cell proliferation, coupled with an increased effect in ERα clearing, in both AE-sensitive and AE-resistant BC cells.